Ambrx Biopharma Shares Jump After Safety, Efficacy Data From Breast Cancer Trial

Ambrx Biopharma Inc's AMAM partner in China, NovoCodex Pharmaceuticals Ltd, presented favorable safety and efficacy data from its ongoing ACE-Breast-01 Phase 1 study of ARX788 at the San Antonio Breast Cancer Symposium (SABCS).

• ARX788 demonstrated treatment effect among patients who previously failed a median of seven anti-HER2 targeting therapies.
• ARX788 demonstrated robust anti-tumor activity, with a disease control rate of 100% in the 29 patients treated at 1.5 mg/kg Q3W.
• One patient who received prior pertuzumab also achieved confirmed partial response (PR).
• The disease control rate among evaluable patients in the 1.5 mg/kg cohort was 100% (29/29).
• ARX788 demonstrated low systemic toxicity and was generally well-tolerated, with most adverse events being grade 1 or 2. No dose-limiting toxicity or drug-related deaths occurred.
• Price Action: AMAM shares are up 11.50% at $9.18 during the market session on the last check Thursday.